Does RISANKIZUMAB-RZAA Cause Gait inability? 258 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 258 reports of Gait inability have been filed in association with RISANKIZUMAB-RZAA. This represents 0.4% of all adverse event reports for RISANKIZUMAB-RZAA.
258
Reports of Gait inability with RISANKIZUMAB-RZAA
0.4%
of all RISANKIZUMAB-RZAA reports
0
Deaths
129
Hospitalizations
How Dangerous Is Gait inability From RISANKIZUMAB-RZAA?
Of the 258 reports, 129 (50.0%) required hospitalization, and 2 (0.8%) were considered life-threatening.
Is Gait inability Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RISANKIZUMAB-RZAA. However, 258 reports have been filed with the FAERS database.
What Other Side Effects Does RISANKIZUMAB-RZAA Cause?
Psoriasis (6,896)
Drug ineffective (2,885)
Pain (2,584)
Fatigue (2,483)
Arthralgia (2,419)
Pruritus (2,311)
Covid-19 (2,145)
Death (1,700)
Fall (1,666)
Surgery (1,662)
What Other Drugs Cause Gait inability?
ADALIMUMAB (3,844)
ETANERCEPT (2,710)
METHOTREXATE (2,559)
TOFACITINIB (2,227)
SECUKINUMAB (2,216)
TOCILIZUMAB (2,139)
LEFLUNOMIDE (2,065)
RITUXIMAB (2,028)
ABATACEPT (2,019)
HYDROXYCHLOROQUINE (1,881)
Which RISANKIZUMAB-RZAA Alternatives Have Lower Gait inability Risk?
RISANKIZUMAB-RZAA vs RISDIPLAM
RISANKIZUMAB-RZAA vs RISEDRONATE
RISANKIZUMAB-RZAA vs RISEDRONIC ACID
RISANKIZUMAB-RZAA vs RISPERDAL
RISANKIZUMAB-RZAA vs RISPERDAL CONSTA